AbbVie says multiple parties vying for assets related to Allergan deal approval

AbbVie Inc said on Friday it was in talks with several parties interested in buying the two assets it intends to divest for the completion of its $63 billion deal to buy drugmaker Allergan Plc. The company said it had notified the U.S. antitrust watchdog of its intention to divest its experimental inflammatory bowel disease therapy, brazikumab, and its treatment for a type of pancreatic disease, Zenpep. The deal, which combines two of the world's biggest pharmaceutical companies, had attracted U.S. Federal Trade Commission's (FTC) scrutiny following a request by a dozen advocacy groups and unions seeking to block the purchase. The agency asked the companies for additional information in September that AbbVie said was not unexpected and that the companies were working through the FTC's requests.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001087 seconds